These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 8383654)

  • 1. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
    Appelbaum PC; Spangler SK; Jacobs MR
    J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
    Venezia RA; Yocum DM; Robbiano EM; Echols RM
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
    Aldridge KE; Morice N; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
    Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
    J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
    Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.